Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02027025 · ClinicalTrials.gov registry record · Phase 2
Study of SPARC1103 in Subjects With Spasticity
A Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT02027025: Completed Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT02027025 is a Phase 2 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02027025, a Phase 2 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
Study of SPARC1103 in subjects with spasticity
Primary Outcome
The modified Ashworth scale is a 6-point scale as follows: Minimum score of 0 (better outcome) = no increase in tone Maximum score of 4 (worst outcome) = affected part(s) rigid in flexion or extension For calculation of modified Ashworth Score, the following scores were assigned to each category of modified Ashworth scale: not testable=NA, 0=0 units, 1=1 unit, 1+ = 2 units, 2 = 3 units, and 4 = 5 units. The total score was the sum of the scores of the 6 lower extremity muscle groups on both le
Interventions
- DRUG SPARC1103 low dose
- DRUG SPARC1103 high dose
- DRUG SPARC Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-04-21 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 2 |
What the finished NCT02027025 record still lists
NCT02027025 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which SPARC1103 low dose is the first listed.
NCT02027025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02027025 about?
NCT02027025 is a clinical study titled "Study of SPARC1103 in Subjects With Spasticity". Study of SPARC1103 in subjects with spasticity
What is the current status of trial NCT02027025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2014-04-21. Estimated completion is 2017-04-28.
What interventions are being tested in trial NCT02027025?
The interventions under investigation include: SPARC1103 low dose (DRUG), SPARC1103 high dose (DRUG), SPARC Placebo (DRUG).
Who is sponsoring clinical trial NCT02027025?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02027025's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI